País: Reino Unido
Língua: inglês
Origem: MHRA (Medicines & Healthcare Products Regulatory Agency)
Balsalazide disodium
Lexon (UK) Ltd
A07EC04
Balsalazide disodium
750mg
Oral capsule
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 01050100
1. WHAT COLAZIDE IS AND WHAT IT IS USED FOR Colazide is used for the treatment of ulcerative colitis (ulceration of the large intestine). It may also be used to keep the disease under control by preventing further episodes. It works as an anti-inflammatory agent. This medicine contains balsalazide disodium as the active ingredient. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE COLAZIDE DO NOT TAKE COLAZIDE: - if you are allergic to balsalazide or any of the other ingredients of this medicine (listed in section 6) - if you are allergic (hypersensitive) to mesalazine, aspirin or other salicylates - if you have a severe liver disease - if you have a moderate to severe kidney disease - if you are pregnant or breast feeding Colazide is not recommended for use in children. WARNINGS AND PRECAUTIONS - asthma - any blood disorders - a mild kidney disorder - a confirmed liver disease - an active ulcer If any of these apply to you, talk to your doctor or pharmacist before taking Colazide. TESTS ON YOUR LIVER, KIDNEY AND BLOOD Before you start treatment with Colazide you will have a blood and urine test to check how well your kidneys are working and what your blood is doing. During treatment your doctor will check how well your liver, kidney and blood is working by taking blood and urine samples periodically during your treatment. CHILDREN Colazide is not recommended in children. OTHER MEDICINES AND COLAZIDE Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. In particular digoxin (used to treat heart problems), methotrexate (used as treatment for some autoimmune diseases, including rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus, some inflammatory bowel diseases (Chron’s disease) and some types of cancer, among other diseases), azathioprine (used to prevent rejection following organ transplantation, and to treat rheumatoid arthritis, some inflammatory bowel diseases (Chron’s disease and ulcerative colitis) and multiple sclerosis among other diseases) and 6-merc Leia o documento completo
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Colazide 750 mg hard Capsules 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 750 mg of balsalazide disodium corresponding to balsalazide 612.8 mg and to mesalazine 262.5 mg. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Capsule, hard. Size 00 beige gelatin capsules. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Colazide is indicated for the treatment of mild-to-moderate active ulcerative colitis and maintenance of remission. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology _Adults: _ TREATMENT OF ACTIVE DISEASE:_ _ _ _ _ _ 2.25g Balsalazide disodium (3 capsules) three times daily (6.75g daily) until remission or for 12 weeks maximum. Rectal or oral steroids can be given concomitantly if necessary. MAINTENANCE TREATMENT: The recommended starting dose is 1.5g Balsalazide disodium (2 capsules) twice daily (3g daily). The dose can be adjusted based on each patient’s response; there may be an additional benefit with a dose up to 6g daily. _Elderly:_ No dose adjustment is anticipated. _Paediatric Population:_ Colazide is not recommended in children. Method of administration To be swallowed whole with or after food. 4.3 CONTRAINDICATIONS Hypersensitivity to the active substance, to its metabolites, including mesalazine, or to any of the excipients listed in section 6.1. History of hypersensitivity to salicylates. Severe hepatic impairment, moderate-severe renal impairment. Pregnant and breast feeding women. 4.4 SPECIAL WARNINGS AND PRECAUTIONS FOR USE Colazide should be used with caution in patients with asthma, bleeding disorders, active ulcer disease, mild renal impairment or those with established hepatic disease. Renal function should be monitored before starting an oral aminosalicylate, at 3 months of treatment, and then annually during treatment (more frequently in renal impairment). Blood disorders can occur with aminosalicylates (see recommendation below). BLOOD DISORDERS During treatment with Leia o documento completo